Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

• Yi Yu,

  Affiliation Biology, ArQule, Inc., Burlington, Massachusetts, United States of America

  ⨯
• Ronald E. Savage ,

  * E-mail: rsavage@ArQule.com

  Affiliation Preclinical Development and Clinical Pharmacology, ArQule, Inc., Burlington, Massachusetts, United States of America

  ⨯
• Sudharshan Eathiraj,

  Affiliation Biology, ArQule, Inc., Burlington, Massachusetts, United States of America

  ⨯
• Justin Meade,

  Affiliation Preclinical Research, South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States of America

  ⨯
• Michael J. Wick,

  Affiliation Preclinical Research, South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States of America

  ⨯
• Terence Hall,

  Affiliation Preclinical Development and Clinical Pharmacology, ArQule, Inc., Burlington, Massachusetts, United States of America

  ⨯
• Giovanni Abbadessa,

  Affiliation Clinical Development, ArQule, Inc., Burlington, Massachusetts, United States of America

  ⨯
• Brian Schwartz

  Affiliation Clinical Development, ArQule, Inc., Burlington, Massachusetts, United States of America

  ⨯